Prosorba column: Phase III data; marketed to treat RA and ideopathic thrombocytopenic purpura (ITP)

CYPB published in Arthritis and Rheumatism previously reported data from its 109-patient Phase III study in which 31.9 percent of Prosorba-treated patients showed improvement in American College of Rh...